On August 30, GARDASIL 9, MSD’s nine-valent human papillomavirus (HPV) vaccine was approved by the China National Medical Products Administration (NMPA) to prevent new indications. This approval marks that the applicable population of GARDASIL 9 has also been expanded to women aged 9-45 years old.
It is reported that the nine-valent HPV vaccine adopts a three-dose immunization program and is suitable for the prevention of:
- Cervical cancer caused by HPV types 16, 18, 31, 33, 45, 52 and 58.
- Cervical intraepithelial neoplasia (CIN1/2/3) and Cervical adenocarcinoma in situ (AIS) caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58.
- And constent infection caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58.